Diagnosis and Treatment of endemic Burkitt Lymphoma in the Pediatric Population in Western Kenya

Jessica Pierre Francois, MS2: Ann Moormann, PhD
University of Massachusetts Medical School – Global Health Pathway Program

Background

Burkitt Lymphoma

- Burkitt Lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma
- 3 subtypes: 1) endemic, 2) sporadic, 3) immunodeficiency/HIV-associated
- In all subtypes:
  - male to female ratio of 2:1
  - t(8,14) translocation of c-myc proto-oncogene

Methods

Diagnostic eBL

1. Biopsy patient via fine-needle aspiration of tumor
2. Smear tumor sample on microscope slide
3. Prepare sample via hematoxylin & eosin-staining method for visualization

Problems with this method

- Average of two weeks for final diagnosis
- Immunohistochemical staining while beneficial is not affordable for all families

Current New Method

1. Biopsy patient via fine needle aspiration of tumor
2. In addition, collect a peripheral blood for control
3. Smear tumor sample on microscope slide
4. Use flow cytometry and fluorescence in situ hybridization (FISH) to analyze tumor sample

Benefits with this method

- Less than one week turn-around for diagnosis
- Therefore treatment efforts start sooner
- Improvement in staging via evaluations of spinal fluid, bone marrow, and imaging

Focusing on Endemic Burkitt Lymphoma (eBL)

- More common compared to other subtypes
- Higher incidence rate in equatorial Africa primarily near the holoendemic malaria belt
- Highly associated with Epstein-Barr-virus (EBV) infection
- Mainly presents in mandible or facial bones; less common in the abdominal region compared to the other subtypes

Objectives

1) To improve the outcomes of children diagnosed with eBL through novel clinical and research approaches between medical institutions in Western Kenya
2) To address the issue of abandonment of treatment in eBL cases

The study is a collaborative effort between the Academic Model Providing Access To Healthcare (AMPATH) which includes Indiana University and the Moi Teaching and Referral hospital (MTRH) in Eldoret, Kenya and the Kenyan Medical Research Institute (KEMRI), which includes Jaramogi Oginga Odinga Teaching and Referral hospital (JOOTRH) in Kisumu Kenya and the University of Massachusetts Medical School (Laboratory of Dr. Moormann).

Barriers to Healthcare

Abandonment of treatment in eBL cases

- Limited resources: lack of chemotherapy drugs
- Financial burdens: transportation issues for patients and their families, inability to afford certain treatments
- Training/Support: training of staff in cancer treatment protocols & diagnostics, educating parents on eBL diagnosis
- Medical personnel strikes: patients cannot receive treatment; patients sent home from hospitals and clinics

Addressing abandonment of treatment

- Financial interventions: transportation cost to medical facilities for patients & families
- Monthly team meetings between MTRH and JOTRH ensures standardized treatment regimen
- Open communication between clinicians and patient families

Future Directions

My Role in Project/Study

- Focusing on the abandonment of care
- Review medical records of patients during the treatment phase of care to assess clinical information and if there are correlations with clinical outcome
- Hypothesis: In regards to complete blood count (CBC), are there key similarities or differences in patients’ CBC at MTRH and JOOTRH during the course of treatment that would indicate clinical outcome?
- Results from this question may encourage more resources and support for transfusions for eBL patients

References


Acknowledgments

I wanted to express my sincere gratitude to these following individuals and institutions:
- Dr. Ann Moormann (Principal Investigator)
- Dr. Catherine Forfini
- Moormann Laboratory members
- Dr. Freida Njogu
- Bower Obeiler
- Pamela Desinges
- Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH)
- University of Massachusetts Medical School
- Academic Model Providing Access To Healthcare (AMPATH)

Works Cited